Previous Close | 31.35 |
1-Year Change | 83.23% |
6-Months Change | 71.22% |
3-Months Change | 39.21% |
Moving Avg (50d) | 27.808 |
Moving Avg (200d) | 22.116 |
ESG Rating | - |
Exchange | NASDAQ |
Market Cap. | 4.33B |
Beta (3-Years) | 1.63 |
Revenue Growth (ttm) | 207.89% |
Net Profit Margin (ttm) | -36.51% |
Return On Assets (ttm) | -10.06% |
EPS (ttm) | -0.97 |
PE Ratio (ttm) | -32.32 |
Dividend Yield | % |
Asset Description: | Denali Therapeutics Inc. |
Predicted Direction: | Sell |
Signal Strength: | Neutral |
Forecast Date: | 2024-11-12 00:00:00 |
Strong Buy | ||
Buy | ||
Neutral | ||
Sell | ||
Strong Sell |
2% | 5% | 7% | 10% | 15% | 20% |
24.908 | 25.641 | 26.129 | 26.862 | 28.083 | 29.304 |
Disclaimer - Please note that the use of AI to analyse contents may occasionally generate incorrect information.
Our cutting-edge algorithms employ macroeconomic data, fundamental and technical analysis indicators to accurately predict the optimal position for short-term trading
By harnessing these signals, we power our asset allocation tools, backtesting tool and portfolio management process, ensuring maximum returns for your investments.
Sector: | Health Care |
Industry: | Biotechnology |
Country: | United States |